肝癌白芨粉栓塞化疗与常规栓塞化疗的比较研究

比较白芨粉栓塞化疗与常规栓塞化疗的临床效果。 46例中晚期肝癌行白芨粉栓塞化疗 ,60例行常规栓塞化疗。两组病例在肿瘤大小、部位、TNM分期、是否合并肝硬化等方面差异无统计学意义 ,P >0 0 5。所有病例随访 1～ 3年。白芨组 1、2、3年累计生存率分别为 84 8% ( 3 9/4 6)、48 7% ( 19/3 9)、42 9% ( 12 /2 8) ,常规组则相应为 68 3 %( 4 1/60 )、3 9 6% ( 19/4 8)、3 6 1% ( 13 /3 6) ,统计学处理是差异有统计学意义 ,P <0 0 5或P <0 0 0 1。白芨粉栓塞化疗对肝癌病灶作用持久 ,杀伤性强 ,远期疗效明显优于常规栓塞化疗

Comparative study on Baiji powder chemoembolization and conventional chemoembolization for hepatocellular carcinoma

The objective is to study comparatively the clinical efficiency of Baiji power transcatheter arterial embolization (TAE) and conventional chemoembolization for hepatocellular carcinomas (HCCs).Baiji power TAE was performed in 46 cases,and conventional chemoembolization in 60 cases.There were no significant differences in the size of tumor,position,TNM stage between the two groups.All patients were followed up for 1 to 3 years.The 1-,2-,and 3-year survival rates were 84.8%(39/46),48.7%(19/39),and 42.9%(12/28) in Baiji group,and 68.3%(41/60),39.6%(19/48) and 36.1%(13/36) in conventional group respectively.A significant difference was found between the two groups.Inconclusion,Baiji powder TAE possesses markedly strong anticancerous effect.It is superior in long-term effectiveness to conventional TAE.